Form 4: Adaptive Biotechnologies Exec Executes Stock Plan

President and COO Julie Rubinstein exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Summary

• Julie Rubinstein, President and COO of Adaptive Biotechnologies, exercised stock options for a total of 56,047 shares between April 17 and April 21, 2026.
• The exercises were conducted at strike prices of $8.46 and $12.14.
• Following the exercises, the reporting person sold a total of 69,061 shares at weighted average prices ranging from $14.55 to $14.66.
• All transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard executive equity management.

Positives

• Transactions were conducted under a pre-planned Rule 10b5-1 trading plan, indicating systematic rather than reactive selling.
• The executive maintains a significant remaining beneficial ownership of 395,146 shares of common stock.

Negatives

• The filing reflects a net reduction in the executive's direct share ownership following the exercise and sale activity.

Risks

• Future share price volatility may impact the value of remaining unexercised options.
• Reliance on Rule 10b5-1 plans does not eliminate market risk for the executive or the company.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is standard practice for executives in the biotechnology sector to manage personal liquidity and tax obligations, and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice among S&P 500 and biotech firms to avoid allegations of insider trading.
• The volume of shares sold is consistent with typical executive compensation and equity vesting schedules observed in mid-cap biotech companies.

Stakeholder Impact

• Minimal impact on shareholders as the sales were pre-scheduled and executed via a 10b5-1 plan.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, Rule 10b5-1, Executive Compensation